Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience
Erin Crotty(Seattle Children's Hospital), Sarah Leary(Seattle Children's Hospital), J. Russell Geyer(Seattle Children's Hospital), James M. Olson(Seattle Children's Hospital), Nathan E. Millard(Seattle Children's Hospital), Aimee Sato(University of Washington), Ralph P. Ermoian(University of Washington), Bonnie Cole(Seattle Children's Hospital), Christina M. Lockwood(Seattle Children's Hospital), Vera Paulson(Seattle Children's Hospital), Samuel R. Browd(Seattle Children's Hospital), Richard G. Ellenbogen(Seattle Children's Hospital), Jason S. Hauptman(Seattle Children's Hospital), Amy Lee(Seattle Children's Hospital), Jeffrey G. Ojemann(Seattle Children's Hospital), Nicholas A. Vitanza(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 35
Abstract
Related Papers
Corticosteroids in brain cancer patients: benefits and pitfalls
Jörg Dietrich, K. Eswara Rao, Sandra Pastorino et al.|Expert Review of Clinical Pharmacology|2011|353